-
Hepatitis C patients without significant fibrosis may be able to delay triple therapy and wait for simpler, shorter, and potentially all-oral regimens that are currently under investigation, researchers said here.
4 hours ago | MedPage Today
-
The quality indicators focus on prevention, testing and assessment, treatment and support, and service organisation related to hepatitis C infection. We will establish a process for reporting on the quality indicators using data from existing national databases.
30 April 2012 | Health Care Improvement Scotland
-
More advanced liver fibrosis, as diagnosed by 2 non-invasive biomarker tests, is associated with a higher risk of death for HIV positive women coinfected with hepatitis C virus (HCV), according to a report in the March 13, 2012, issue of AIDS.
11 April 2012 | HIVandHepatitis.com
-
Despite outrage from activists, Merck refused to study drug-drug interactions (DDIs) between boceprevir (Victrelis), their HCV protease inhibitor, and drugs commonly used to treat HIV, putting coinfected study volunteers at risk for drug-drug interactions in their own clinical trial.
10 April 2012 | TAG
-
Important preliminary recommendations involving the use of hepatitis C protease inhibitors among people living with HIV are provided by U.S. Department of Health and Human Services panelists in the March 27 update to the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.
03 April 2012 | AIDSMeds
-
Getting rid of acute hepatitis C virus (HCV) infection once—whether it is cleared by strong immune response during the initial months of infection or cured with treatment — does not protect HIV-positive men who have sex with men (MSM) against reinfection with the virus, according to new data presented on Tuesday, March 6, at the 19th Conference on Retroviruses and Opportunistic Infections in Seattle.
27 March 2012 | AIDSMeds
-
NICE is recommending Janssen’s hepatitis C pill Incivo for funding on the NHS in England. The drug has bypassed the preliminary NICE stages and has gone straight
to final draft guidance, with a decision expected by June.
20 March 2012 | InPharm
-
Health care providers are being reminded not to prescribe certain cholesterol-reducing medications—notably members of the “statin” drug class—for people living with hepatitis C virus (HCV) using either Incivek (telaprevir) or Victrelis (boceprevir), according to a recent U.S. Food and Drug Administration (FDA) letter.
01 March 2012 | AIDSMeds
-
The European Medicines Agency has recommended updating the prescribing
information for Victrelis (boceprevir) with information about drug interactions
between this hepatitis C medicine and the ritonavir-boosted HIV protease
inhibitors atazanavir, darunavir and lopinavir.
18 February 2012 | European Medicines Agency
-
The hepatitis C protease inhibitor Victrelis (boceprevir) has some significant drug-drug interactions with common Norvir (ritonavir)-boosted protease inhibitor (PI) combinations, according to preliminary data from a clinical trial and a warning issued to health care providers by Merck on February 6.
08 February 2012 | AIDSMeds
Talking points: a checklist for you and your doctorTalking points is designed to help you talk to your doctor about HIV
treatment.
Preventing HIVAn essential resource providing evidence-based information on preventing HIV infection. 
HIV, stigma and discrimination is now available in print!17 May 2012This week, boxes of the brand-new edition of our booklet...
Come and see us at the BHIVA conference!18 April 2012This morning, I boarded a train at Euston with one...
Community action on harm reduction (CAHR)16 April 2012We’ve been working on the design and
development of a new...